Compass Therapeutics (CMPX) Interest Expenses (2018 - 2021)

Compass Therapeutics has reported Interest Expenses for 9 years, with the latest figure at $32.5 million in Q1 2026.

• Quarterly Interest Expenses rose 1413.19% year-over-year to $32.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.5 million (up 1413.19% YoY) and the FY2025 annual result came in at $79.2 million, up 33.11% from the prior year.
• Interest Expenses climbed to $32.5 million in Q1 2026 per CMPX's latest filing, from $100000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $32.5 million in Q1 2026 and troughed at $100000.0 in Q4 2023.
• A 5-year average of $3.8 million and a median of $463500.0 in 2022 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses sank 95.97% in 2024, then surged 6964.0% in 2025.
• Over 5 years, Interest Expenses stood at $300000.0 in 2022, then slumped by 66.67% to $100000.0 in 2023, then soared by 1700.0% to $1.8 million in 2024, then sank by 94.44% to $100000.0 in 2025, then jumped by 32373.0% to $32.5 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $32.5 million, $100000.0, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.